Concepedia

Hans-Peter Vornlocher

HV

Statistics

Publications

5

Citations

1.3K

H-Index

5

Active since

1997

Affiliations

Massachusetts Institute of Technology(Current)

Moderna Therapeutics (United States)

Alnylam Pharmaceuticals (United States)

The University of Texas Southwestern Medical Center

Hans-Peter Vornlocher is an author at Massachusetts Institute of Technology specializing in gene expression, medicine, and non-coding rna.

Top concepts

Publications per year

1997–2016

5

Publications

5

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Maria Frank-Kamenetsky, Aldo Grefhorst, Norma N. Anderson et al. · Proceedings of the National Academy of Sciences · 2008 · 635 citations · Full text

Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection

Christine I. Wooddell, David B. Rozema, Matthias John et al. · Molecular Therapy · 2013 · 289 citations · Full text

Structure of cDNAs Encoding Human Eukaryotic Initiation Factor 3 Subunits

Katsura Asano, Hans-Peter Vornlocher, Nancy J. Richter-Cook et al. · Journal of Biological Chemistry · 1997 · 165 citations · Full text

Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway

Matthias John, Rainer Constien, Akin Akinc et al. · Nature · 2007 · 145 citations · Full text

, , +7

Hepatitis B virus genome replication triggers toll-like receptor 3-dependent interferon responses in the absence of hepatitis B surface antigen

C.I. Real, Mengji Lu, Jia Liu et al. · Scientific Reports · 2016 · 20 citations · Full text

1–5 of 5